抗体
计算生物学
内吞作用
建筑
计算机科学
化学
体内
单域抗体
约束(计算机辅助设计)
生物
噬菌体展示
表位
动力学(音乐)
细胞生物学
药代动力学
作者
Stefan Christopher Weise,Cordula Jany,Sabine Imhof-Jung,Claire Simonneau,Johannes Fraidling,Anna‐Lena Bolender,Aman Padamsey,Elisa Di Lenarda,Anne Christine Cascais,Thomas Emrich,Tilman Schlothauer,Annette Indlekofer,Hubert Kettenberger,Volker Haucke,W. Richter,Thomas E. Kraft
出处
期刊:
[Cold Spring Harbor Laboratory]
日期:2026-11-04
标识
DOI:10.64898/2026.11.02.763654
摘要
ABSTRACT Complex antibody formats are advancing in the biotherapeutic landscape to address the need for multi-specificity, tailored valency, and novel mechanisms of action. However, understanding how non-canonical architectures impact fundamental pharmacokinetic pathways remains a critical challenge. While canonical IgGs experience steric hindrance at the endosomal membrane during FcRn engagement, whether – and how strongly – this constraint impacts FcRn-mediated recycling across the expanding diversity of non-canonical antibody architectures has remained unknown. By systematically evaluating a diverse panel of rationally designed antibody geometries utilizing orthogonal in vitro assays we demonstrate that spatial layout profoundly influences FcRn-recycling efficiency; inverting the antibody structure by positioning the Fab-domains to the C-terminus (‘invertbodies’) maximizes recycling, whereas crowding the N-terminus severely impairs it. In contrast, non-specific endocytosis was only modestly and inconsistently affected by Fab number, dependent on the Fv-sequence, but not by the spatial architecture itself. Notably, antibody architecture and affinity-enhancing Fc-FcRn mutations act independently yet cooperatively, ultimately revealing a physiological ‘recycling ceiling’. These FcRn-recycling dynamics translate with high fidelity to in vivo clearance (CL) in a humanized FcRn mouse model. Across the antibody panel, architecture drove a near 15-fold variance in CL, an effect that collapsed in FcRn-knockout mice. As proof of concept, we applied the invertbody design to a variant of the marketed antibody golimumab, achieving a three-fold reduction in clearance without compromising potency. These findings reveal the magnitude and predictability with which the antibody architecture governs FcRn-recycling and non-specific CL, establishing a rational, generalizable framework to optimize the pharmacokinetics of biotherapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI